Tetra Bio-Pharma Closes Financing With Aphria Inc.
Tetra Bio-Pharma Inc. has closed a private placement of units with its strategic partner Aphria Inc.
Tetra Bio-Pharma Bolsters Intellectual Property Position and Product Pipeline
Tetra Bio-Pharma Inc. and Altus Formulation Inc. today announced the signing of a non-binding term sheet to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications.
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
Tetra Bio-Pharma Inc. is pleased to update the market that Dr. Guy Chamberland , CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
Tetra Bio-Pharma Inc. is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a source of supply for a specialized cannabis smoke air purifying system and a mask designed for law and emergency responders.
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
Tetra Bio-Pharma Inc. and Quantum Pharma Inc. today announced the signing of a binding proposal for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations.
Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs
Tetra Bio-Pharma Inc. today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines.
Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs
Tetra Bio-Pharma Inc. is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs. The Corporation also announced the conclusion of the dividend-in-kind of North Bud Farms Inc.
Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.
Tetra Bio-Pharma Inc. today announced it has entered into a non-binding proposal (the "Proposal") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction").
Tetra Natural Health Signs Exclusive Agreement for the Distribution of their Hemp Energy Drink in Canada and the USA
Tetra Natural Health Inc. today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001
Tetra Bio-Pharma Inc. today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.